CCNE1 and breast cancer: The experimental results showed that CCNE1 knockdown can partially restore sensitivity to palbociclib in MCF‐7/R cells and bring us new inspiration that targeting CCNE1 may sensitize ER+ BC to palbociclib therapy (Figure S8).